Good news, bad news for Impax

The FDA has given tentative approval for an ANDA for a generic version of Eli Lilly's Cymbalta, a drug that treats depression and general anxiety. At the heart of the new drug is Impax Laboratories' drug delivery technology, a Hayward, CA-based company that specializes in controlled release for generics. TradingMarkets.com reports that Cymbalta saw $3 billion in U.S. sales this past year. That was the good news for Impax. The bad news is that it is being sued by a unit of Johnson & Johnson over alleged patent infringement in its attempt to market a generic version of the ADHD drug Concerta. Generic Cymbalta report |  Generic Concerta news

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.